Clinical trials in Ranica – page 12

2 668 clinical trials in Ranica, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Ranica at a glance

2 668

clinical trials

Research sites1

Quick filters

2 668 trials in Ranica

Open in trial search

Gastric cancer+2

Recruiting

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Non-small cell lung cancer

Recruiting

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:AstraZeneca AB

Contact Research Centre

Clear cell renal cell carcinoma

Recruiting

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:AB521
Sponsor:Arcus Biosciences Inc.

Contact Research Centre

Non-small cell lung cancer stage IV+2

Recruiting

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Colorectal cancer metastatic+1

Recruiting

Study of melphalan followed by trifluridine-tipiracil and bevacizumab combination versus trifluridine-tipiracil and bevacizumab in liver metastatic colorectal cancer

Registered drugNo placebo

Study of melphalan followed by trifluridine-tipiracil and bevacizumab combination versus trifluridine-tipiracil and bevacizumab in liver metastatic colorectal cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Delcath Systems Inc.

Contact Research Centre

Pancreatic carcinoma

Recruiting

Evaluation of Hydrocortisone, Octreotide, and Teres Ligament Patch Combination to Prevent Complications After Pancreatoduodenectomy in Patients with Pancreatic Head Cancer or IPMN

Registered drugNo placebo

Evaluation of Hydrocortisone, Octreotide, and Teres Ligament Patch Combination to Prevent Complications After Pancreatoduodenectomy in Patients with Pancreatic Head Cancer or IPMN

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Hydrocortisone
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Triple negative breast cancer+2

Recruiting

Study on Atorvastatin's Role in Enhancing Immunotherapy for Patients with Triple Negative Breast Cancer and Non-Small Cell Lung Cancer

Registered drugNo placebo

Study on Atorvastatin's Role in Enhancing Immunotherapy for Patients with Triple Negative Breast Cancer and Non-Small Cell Lung Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Atorvastatin
Sponsor:Universita Degli Studi Di Padova

Contact Research Centre

Ischaemic stroke

Recruiting

Study on JX10 for Improving Outcomes in Patients with Acute Ischemic Stroke

Investigational

Study on JX10 for Improving Outcomes in Patients with Acute Ischemic Stroke

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:JX10
Sponsor:Corxel Pharmaceuticals Co. Ltd.

Contact Research Centre

Amyotrophic lateral sclerosis

Recruiting

Study on the Effects of Acetylcarnitine Hydrochloride in Patients with Amyotrophic Lateral Sclerosis (ALS)

Registered drug

Study on the Effects of Acetylcarnitine Hydrochloride in Patients with Amyotrophic Lateral Sclerosis (ALS)

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Acetylcarnitine hydrochloride
Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Contact Research Centre

Lupus nephritis

Recruiting

Study on Obinutuzumab for Adolescents with Active Lupus Nephritis and Safety in Children Aged 5 to 12

Registered drug

Study on Obinutuzumab for Adolescents with Active Lupus Nephritis and Safety in Children Aged 5 to 12

Registered drug

Italy

Participants:0–17 years
Substances:Obinutuzumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of Amivantamab, Lazertinib, and Pemetrexed for Patients with Advanced or Metastatic Solid Tumors, Including EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

Study of Amivantamab, Lazertinib, and Pemetrexed for Patients with Advanced or Metastatic Solid Tumors, Including EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Amivantamab
Sponsor:Janssen Cilag International

Contact Research Centre

Prostate cancer metastatic

Recruiting

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

InvestigationalNo placebo

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Darolutamide
Sponsor:Unicancer

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Ranica

What the registry says about research in the country

01 Glomerulonephritis Studies

Innovative research focusing on membranoproliferative glomerulonephritis and related conditions, evaluating novel therapeutic approaches including iptacopan and pegcetacoplan for treating various forms of kidney inflammation.

IC-MPGN Treatment Evaluation
C3 Glomerulopathy Research
Post-Transplant Recurrence Studies

Multiple trials aim to reduce proteinuria and improve long-term kidney function outcomes.

02 Nephropathy Research

Comprehensive studies examining treatments for IgA Nephropathy and membranous nephropathy, including investigations of sparsentan and specialized antibody therapies for patients resistant to conventional treatments.

Primary Membranous Nephropathy
IgA Nephropathy Interventions
Antibody-Based Treatments

Focus on proteinuria reduction and preservation of renal function in various nephropathy types.

03 Chronic Kidney Disease

Advanced research into non-diabetic chronic kidney disease, exploring new therapeutic options including finerenone and investigating treatments for complications like hyperkalemia.

Disease Progression Prevention
Hyperkalemia Management
Long-term Kidney Function

Studies aim to delay disease progression and improve standard of care outcomes.

Back to Italy All countries